UnitedHealth Group Incorporated (UNH)
UnitedHealth Group: Buy This Bargain Before It's Gone
On October 15, UnitedHealth Group published financial results for the third quarter of 2024, which surprised me primarily due to the sharp increase in Optum Rx revenue. Optum Rx's revenue reached about $34.2 billion in the third quarter of 2024, up 18.5% year-on-year. Overall, due to year-over-year revenue growth in UnitedHealth Group's two main divisions, Optum and UnitedHealthcare, it repurchased shares worth $1.7 billion in Q3 2024.
Beyond UnitedHealth's Q3 Earnings: Time to Reevaluate & Sell Stock?
Looking ahead to 2025, UNH projects adjusted earnings to reach around $30 per share at the top end, which falls short of the Zacks Consensus Estimate.
UnitedHealth: Expect A New Normal In CMS Funding - Maintain Buy
The market has over-reacted to UNH's cautious FY2025 guidance, since the lower bottom-line is attributed to "CMS payment cuts, the IRA, and a mismatch between Medicaid rates and medical program." Given the recently released Star rating for 2025, we believe that the redeterminations and higher medical costs may be a new normal across the health care provider industry. For now, UNH has attempted to optimize its operations while managing the Optum therapy/ drug costs, resulting in the segment's growing profit margins and decent FY2024 guidance.
UnitedHealth Group Pulls Back Into A Healthy Buying Opportunity
UnitedHealth Group's UNH stock price pulled back following the Q3 earnings release in what can best be described as a temper tantrum. The results weren't bad, outpacing the consensus estimates and compounded by solid guidance, but the market wanted more, so it sold off.
Elevance Health: Why Invest Over UnitedHealth Group?
Despite a disappointing Q3 report, Elevance Health remains attractive due to its relatively favorable valuation compared to UnitedHealth Group and a total shareholder yield of roughly 3.5%. Elevance's expansion into healthcare services through Carelon and continued strength in Medicare and Medicaid markets support long-term growth, especially given the industry's demographic tailwinds. Though 2024 is a “reset” year, Elevance management's outlook for 2025 and beyond points to strong potential margin recovery and continued earnings growth.
Should You Pick UNH Stock At $560?
UnitedHealth Group (NYSE: UNH) recently reported its Q3 results, with revenues and earnings exceeding our expectations. The company reported revenue of $100.8 billion and adjusted earnings of $7.15 per share, compared to our estimates of $99 billion and $6.95, respectively.
UnitedHealth Group Pulls Back Into a Healthy Buying Opportunity
UnitedHealth Group's NYSE: UNH stock price pulled back following the Q3 earnings release in what can best be described as a temper tantrum. The results weren't bad, outpacing the consensus estimates and compounded by solid guidance, but the market wanted more, so it sold off.
Why 5 Of 6 UnitedHealth Analysts Are Cutting Forecasts After Q3 Earnings Release
UnitedHealth Group Inc UNH reported on Tuesday upbeat earnings for its third quarter.
UnitedHealth Q3 Earnings Review: Deserved Sell-Off Is Not A 'Buy The Dip' Opportunity (Rating Downgrade)
UnitedHealth's Q3 earnings, released yesterday, revealed significant challenges, including rising healthcare costs and reduced rate increases, impacting profitability and leading to an 8% stock drop. Medicare Advantage headwinds and increased medical benefit ratios are squeezing margins, making the business less profitable than a year ago. The company has struggled with implementing value-based care, which was supposed to reduce costs but hasn't yet delivered the expected savings.
Brokers Suggest Investing in UnitedHealth (UNH): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
UnitedHealth Stock Plunges After Earnings, But It's A Buy Now
UnitedHealth Group's stock fell 8.1% despite beating Q3 estimates due to conservative 2024 and 2025 EPS guidance. However, I rate it as a Buy. The company's long-term EPS growth target of 13-16% is achievable, supported by the company's strong track record. UNH's current valuation is attractive, trading at a P/E ratio that aligns with historical trends, suggesting potential for double-digit annual returns based on expected EPS growth.
UnitedHealth is still a 'gold standard stock' after earnings drop: Cantor Fitzgerald's Sarah James
Sarah James, Cantor Fitzgerald, joins 'Fast Money' to talk how she is playing UnitedHealth's stock right now.
